GSK completes study for COPD treatment

Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

By MoneyWeek

published 24 August 2012

in Features

The 6,000-patient study, along with other recently completed studies, "supports GSK's plans to commence global regulatory submissions for UMEC/VI from the end of 2012," the firm said.

UMEC/VI is one of several late-stage assets in Glaxo's respiratory development portfolio which have not yet been approved anywhere in the world.